Oncology Drug Approval News Flash: FDA Approves Brexucabtagene Autoleucel (Tecartus, Kite/Gilead) for Relapsed/Refractory Mantle Cell Lymphoma

On April 2, 2026, the U.S. Food and Drug Administration (FDA) granted traditional (full) approval to brexucabtagene autoleucel (Tecartus^®), a CD19-directed autologous CAR T-cell therapy developed by Kite Pharma (a Gilead Sciences company), for adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL). The full approval converts the prior accelerated approval and is supported by confirmatory data from Cohort 3 of the ZUMA-2 trial in Bruton tyrosine kinase inhibitor (BTKi)-naïve patients, showing an objective response rate (ORR) of 91% and a complete response (CR) rate of 79%. This article summarizes the pivotal trial design, key efficacy outcomes, safety profile, and the regulatory and clinical positioning of this approval.

Target Patient Population

• Adults (≥18 years)
• Histologically confirmed mantle cell lymphoma (MCL)
• Relapsed or refractory after one or more prior lines of therapy
• Inclusive of BTKi-naïve patients
• Fit for leukapheresis and lymphodepleting chemotherapy

Pivotal Trial Overview

The confirmatory evidence supporting this approval comes from the ZUMA-2 trial (NCT02601313), an open-label, single-arm, multicenter Phase 2 study in R/R MCL conducted across three cohorts.

Brexucabtagene autoleucel is manufactured from each patient’s own T cells, which are collected by leukapheresis and transduced with a lentiviral vector encoding an anti-CD19 chimeric antigen receptor. After lymphodepleting chemotherapy with fludarabine and cyclophosphamide, patients receive a single intravenous infusion at a target dose of 2 × 10⁶ CAR-positive T cells/kg (up to 2 × 10⁸). A distinguishing feature of Tecartus, relative to Yescarta (axicabtagene ciloleucel) which shares the same CAR construct, is an additional T-cell enrichment step in manufacturing designed to remove circulating leukemia-like cells frequently seen in MCL—optimizing the product for this disease setting.

In Cohort 3, patients with R/R MCL having at least one prior line of therapy at the time of leukapheresis were enrolled, while patients with prior BTKi exposure were excluded. The primary endpoint was centrally-reviewed ORR; key secondary endpoints included CR rate, duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. The study was conducted at 18 sites across the United States, Europe, and Canada.

Key Efficacy Results

Cohort 3 results (BTKi-naïve, N=86; data cut-off at a median follow-up of 23.0 months) are summarized below.

Historically, R/R MCL — particularly after BTKi failure — has been associated with median survival of one to two years, and chemoimmunotherapy ORRs in the 20–40% range. The 91% ORR / 79% CR observed in Cohort 3 confirms that high activity is preserved in BTKi-naïve patients as well, mirroring the original accelerated approval cohort (BTKi-experienced, July 2020) which reported ORR 87% / CR 62%. The confirmatory evidence reinforces that deep responses are achievable across the BTKi treatment-history spectrum.

In the longer follow-up of the original Cohorts 1+2, approximately 25–30% of patients remain progression-free at three years and approximately 50% remain alive at three years — indicating durable remissions in a meaningful subset, while late relapses continue to occur. Long-term outcomes for Cohort 3 are expected to be updated at upcoming hematology meetings and peer-reviewed publications.

Safety Profile

Pooled safety data across all cohorts (N=168) reflect a toxicity pattern typical of CD19-directed CAR T-cell therapy.

The product label carries multiple Boxed Warnings: (1) life-threatening cytokine release syndrome; (2) immune effector cell-associated neurotoxicity syndrome (ICANS) and other neurologic toxicities; (3) frequent and prolonged cytopenias; (4) serious infections; and (5) secondary hematologic malignancies, including T-cell malignancies. Administration is restricted to certified centers and qualified providers under a Risk Evaluation and Mitigation Strategy (REMS) program. Mandatory site requirements include pre-positioned tocilizumab availability, ICU back-up capability, and the use of validated ICANS scoring protocols.

Cohort 3-specific Grade 5 events, secondary T-cell malignancy incidence, and long-term safety remain subjects of post-marketing commitment surveillance.

Regulatory and Clinical Significance

The regulatory implications can be organized along three axes.

(1) A successful accelerated-to-traditional conversion. Tecartus first received accelerated approval on July 24, 2020, based on Cohort 1 data, making it the first CAR T-cell therapy approved in the U.S. for any MCL indication. The current full approval reflects fulfillment of the confirmatory-evidence obligation under FDA’s accelerated approval pathway — a textbook example of the early-to-full approval progression that the framework was designed to enable.

(2) Indication expansion: confirmatory evidence in BTKi-naïve patients. Because the original Cohorts 1+2 enrolled BTKi-experienced patients, real-world practice tended to position Tecartus as a salvage option after BTKi failure. The confirmatory data in BTKi-naïve patients provide regulatory grounding for considering this therapy across the BTKi treatment-history spectrum, and may particularly support its earlier consideration in younger, fit patients for whom CAR T-cell therapy can be a primary treatment choice over chemoimmunotherapy.

(3) CAR T-cell therapy’s place in the evolving MCL treatment map. The R/R MCL therapeutic landscape has expanded rapidly to include lisocabtagene maraleucel (Breyanzi, approved July 2024 in MCL), BCL-2 inhibition with venetoclax, the non-covalent BTKi pirtobrutinib, and bispecific (CD20×CD3) antibodies. Tecartus retains a distinctive position as the first CAR T-cell therapy in MCL and now carries traditional approval data spanning the BTKi treatment-history spectrum. With multiple modalities now available, the central clinical question shifts from “is CAR T-cell therapy feasible?” to optimal sequencing of CAR T cells, bispecifics, BTKi, and BCL-2 inhibition.

This approval is a U.S. regulatory action. Approval status, labeled indications, and site-of-care requirements differ in other jurisdictions. Clinicians outside the U.S. should consult their local regulatory approvals, prescribing information, and treatment guidelines when considering CAR T-cell therapy for R/R MCL.

My Thoughts and Future Outlook

Mantle cell lymphoma has been a disease whose treatment map has been rewritten repeatedly: rituximab-based chemoimmunotherapy, autologous transplantation, ibrutinib, venetoclax, and now CAR T-cell therapy. The 91% ORR and 79% CR seen with Tecartus in Cohort 3 mean that, for the right patient, a treatment capable of delivering the deepest possible remission can now be considered earlier in the disease course — not only after BTKi failure.

And yet, the harder question — when, and to whom, this therapy should be offered — remains open. Grade ≥3 neurologic events in roughly one in three patients, severe infections at a similar rate, and the residual risk of secondary malignancies are not trivial considerations to weigh against the depth of response. As newer BTKi options, bispecific antibodies, and post-ASCT consolidation strategies continue to mature, the clinical community will need to define which patients should receive CAR T-cell therapy upfront, and which patients are better served by sequential approaches. Longer follow-up of Cohort 3 — and analyses of remission quality, including measurable residual disease and CAR persistence — will sharpen those judgments.

From a translational and regulatory perspective, this approval is a clean instance of the accelerated approval framework functioning as intended. What now limits real-world impact is less about the data and more about delivery: vein-to-vein time, the geographic distribution of qualified centers with ICU back-up, and reimbursement variability across systems. The science has caught up. The next constraint is quietly and reliably bringing the therapy to the patients who need it.

This article was compiled and summarized by Morningglorysciences based on FDA public materials, the official Kite/Gilead press release, peer-reviewed publications of the ZUMA-2 trial, and related sources. Treatment decisions should always be made in reference to the original publications, the most recent prescribing information, and local clinical practice guidelines.